Answer
The mean terminal half-life of mepolizumab after subcutaneous administration ranges from 16 to 22 days.
Sources for this answer
- Nucala 100 mg solution for injection in pre-filled penGlaxoSmithKline UK · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked